Review



elispot reader s6 ultra m2  (Cellular Technology Ltd)


Bioz Verified Symbol Cellular Technology Ltd is a verified supplier
Bioz Manufacturer Symbol Cellular Technology Ltd manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Cellular Technology Ltd elispot reader s6 ultra m2
    Elispot Reader S6 Ultra M2, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/S6+Ultra+M2/bio_rxiv__64898__2026__03__18__712579-225-8-13
    Average 99 stars, based on 38 article reviews
    elispot reader s6 ultra m2 - by Bioz Stars, 2026-09
    99/100 stars

    Images

    Related Articles

    Enzyme-linked Immunospot:

    Article Title: Rapid-Turnaround Co-Administration of mRNA-Based MHC-I and MHC-II-Restricted Neoantigens Enhances Immune Responses of Antigen-Specific CD8 + T Cells and Anti-Cancer Efficacy in Colorectal Cancer.
    Article Snippet: After washing the plates, an ELISpot assay was performed following the manufacturer’s protocol (Cat. 3321–4APT, Mabtech, Nacka Strand, Sweden). .. The spots were counted using an ELISpot reader (ImmunoSpot Software, C.T.L corporation, Beaverton, OR, USA). ..

    Article Title: Differential replication, pathology, and immune response of clade IIb mpox virus in C57BL/6 and BALB/c mice.
    Article Snippet: The reactions were developed with KPL TrueBlue Peroxidase substrates (Seracare Life Sciences). .. The number of virus foci was counted using an ELISpot reader (Cellular Technology Ltd), and the focus forming units (FFUs) per mL were calculated through the formula: average spots × virus dilution times×10 (FFU/mL). ..

    Article Title: Protein antigens and uses thereof
    Article Snippet: .. Plates are developed according to the manufacturer's protocol, and analyzed on an ELISPOT reader (Cellular Technology Ltd.) with accompanying software. ..

    Article Title: Rapid‐Turnaround Co‐Administration of mRNA‐Based MHC‐I and MHC‐II‐Restricted Neoantigens Enhances Immune Responses of Antigen‐Specific CD8 + T Cells and Anti‐Cancer Efficacy in Colorectal Cancer
    Article Snippet: After washing the plates, an ELISpot assay was performed following the manufacturer's protocol (Cat. 3321–4APT, Mabtech, Nacka Strand, Sweden). .. The spots were counted using an ELISpot reader (ImmunoSpot Software, C.T.L corporation, Beaverton, OR, USA). ..

    Article Title: Antigen-Dependent Adjuvanticity of Poly(lactic-co-glycolic acid)-polyethylene Glycol 25% Nanoparticles for Enhanced Vaccine Efficacy.
    Article Snippet: .. The plates were rinsed with plenty of water to terminate the color development and counted in an ELISPOT reader (Cellular Technology Limited, Cleveland, OH, USA). .. A total of 100 μL of S. aureus (strain ATCC 25923) at different concentrations (for the 1 × LD100 lethal challenge group, the concentration of S. aureus was 2.56 × 109 CFU/mL; for the 2 × LD100 lethal challenge group, the concentration of S. aureus was 5.12 × 109 CFU/mL; and for the 4 × LD100 lethal challenge group, the concentration of S. aureus was 1.024 × 1010 CFU/mL) were administered intravenously to the mice on the 35th day after prime immunization.

    Article Title: Bispecific antibody targeting shared indel-derived neoantigen of APC
    Article Snippet: Interferon (IFN)-γ secretion from T cells were detected by ELISPOT assay using Human IFN-γ ELISpotPRO kit (MABTECH, Stockholm, Sweden) according to the manufacturer’s instruction. .. Spots were captured and analyzed by an automated ELISPOT reader, ImmunoSPOT S4 (Cellular Technology Ltd, Shaker Heights, OH, USA) and the ImmunoSpot Professional Software package, Version 5.1 (Cellular Technology Ltd). .. Cell viability was assayed by CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

    Article Title: Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines
    Article Snippet: IFNγ produced upon re-activation of peptide-specific T cells and captured on anti-IFNγ capture antibody was visualized via sequential addition of 2 μg/mL biotinylated anti-IFNy detection antibody (BD #51-1818KA), Streptavidin-Horseradish Peroxidase (HRP) (BD #557630) and AEC chromogen substrate (BD #551951) as per manufacturer’s protocol. .. After overnight drying, the ELISPOT plates were imaged in an ELISPOT reader (Cellular Technology, Ltd), and bound IFNγ was calculated as Spot Forming Units (SFUs) per 1 ×10 6 splenocytes. ..

    Article Title: Comparison of homologous and heterologous vaccination strategies for combating disease caused by Burkholderia pseudomallei
    Article Snippet: .. Spots were scanned with an automated ELISpot reader (CTL-Immunospot S6 Analyzer, CTL, Germany) using the ImmunoSpot ® software. ..

    Virus:

    Article Title: Differential replication, pathology, and immune response of clade IIb mpox virus in C57BL/6 and BALB/c mice.
    Article Snippet: The reactions were developed with KPL TrueBlue Peroxidase substrates (Seracare Life Sciences). .. The number of virus foci was counted using an ELISpot reader (Cellular Technology Ltd), and the focus forming units (FFUs) per mL were calculated through the formula: average spots × virus dilution times×10 (FFU/mL). ..

    Software:

    Article Title: Protein antigens and uses thereof
    Article Snippet: .. Plates are developed according to the manufacturer's protocol, and analyzed on an ELISPOT reader (Cellular Technology Ltd.) with accompanying software. ..

    Article Title: Bispecific antibody targeting shared indel-derived neoantigen of APC
    Article Snippet: Interferon (IFN)-γ secretion from T cells were detected by ELISPOT assay using Human IFN-γ ELISpotPRO kit (MABTECH, Stockholm, Sweden) according to the manufacturer’s instruction. .. Spots were captured and analyzed by an automated ELISPOT reader, ImmunoSPOT S4 (Cellular Technology Ltd, Shaker Heights, OH, USA) and the ImmunoSpot Professional Software package, Version 5.1 (Cellular Technology Ltd). .. Cell viability was assayed by CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

    Article Title: Comparison of homologous and heterologous vaccination strategies for combating disease caused by Burkholderia pseudomallei
    Article Snippet: .. Spots were scanned with an automated ELISpot reader (CTL-Immunospot S6 Analyzer, CTL, Germany) using the ImmunoSpot ® software. ..



    Similar Products

    86
    Mabtech Inc astor elispot reader
    Astor Elispot Reader, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/elispot+fluorospot+iris+mabtech+reader/pm42310741-96-14-17
    Average 86 stars, based on 1 article reviews
    astor elispot reader - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Mabtech Inc iris elispot fluorospot reader
    Iris Elispot Fluorospot Reader, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/elispot+fluorospot+iris+mabtech+reader/pmc13260466-90-26-29
    Average 86 stars, based on 1 article reviews
    iris elispot fluorospot reader - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Mabtech Inc elispot reader
    Elispot Reader, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/elispot+fluorospot+iris+mabtech+reader/pm42150061-364-10-12
    Average 86 stars, based on 1 article reviews
    elispot reader - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    99
    Cellular Technology Ltd elispot reader s6 ultra m2
    Elispot Reader S6 Ultra M2, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/S6+Ultra+M2/bio_rxiv__64898__2026__03__18__712579-225-8-13
    Average 99 stars, based on 1 article reviews
    elispot reader s6 ultra m2 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Cellular Technology Ltd aid classic elispot plate reader
    Magnitude and specificity of T cell memory responses generated by 899-day infection (A) Ex vivo <t>IFNγ-ELISpot</t> well images. DMSO control unstimulated wells and wells stimulated with overlapping peptides covering S1 and S2 region of Spike (duplicates shown), or single peptides S51 and S134. (B) Total magnitude of SARS-CoV-2-specific memory T cell response to structural proteins Spike, membrane (M), nucleoprotein (NP) and open reading frame 3a (ORF3a) and RTC proteins (NSP7, NSP12 polymerase, and NSP13 helicase) colored by protein targeted and measured after persistent infection (>900 days). (C and D) Total magnitude of SARS-CoV-2-specific T cell response (C) or T cell response to Structural and RTC proteins (D) in pre-pandemic samples (pre-August 2019), in exposed healthcare workers (HCW) who remained seronegative, including abortive infections, and in HCW with laboratory confirmed SARS-CoV-2 infections (samples 4 months post-exposure/infection in June to July 2020) for comparison to T cell response in persistently infected patient. (E) Ratio of the magnitude of the T cell response to RTC/structural T cells. Percentage of cohort with a response above 1 (stronger response to RTC than structural proteins) shown below. (F) Magnitude of T cell response to a pool of epitopes from Flu, EBV, and CMV. (B–E) Subset of data previously published in Swadling et al. (A–F) IFNγ-ELISpot. (C and D) Box and Whisker, Tukey. (C–F) Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p < 0.0001. (E and F) Bars, geomean.
    Aid Classic Elispot Plate Reader, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/S6+Universal+M2/pmc12936837-401-18-23
    Average 99 stars, based on 1 article reviews
    aid classic elispot plate reader - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    86
    Mabtech Inc mabtech elispot reader
    Magnitude and specificity of T cell memory responses generated by 899-day infection (A) Ex vivo <t>IFNγ-ELISpot</t> well images. DMSO control unstimulated wells and wells stimulated with overlapping peptides covering S1 and S2 region of Spike (duplicates shown), or single peptides S51 and S134. (B) Total magnitude of SARS-CoV-2-specific memory T cell response to structural proteins Spike, membrane (M), nucleoprotein (NP) and open reading frame 3a (ORF3a) and RTC proteins (NSP7, NSP12 polymerase, and NSP13 helicase) colored by protein targeted and measured after persistent infection (>900 days). (C and D) Total magnitude of SARS-CoV-2-specific T cell response (C) or T cell response to Structural and RTC proteins (D) in pre-pandemic samples (pre-August 2019), in exposed healthcare workers (HCW) who remained seronegative, including abortive infections, and in HCW with laboratory confirmed SARS-CoV-2 infections (samples 4 months post-exposure/infection in June to July 2020) for comparison to T cell response in persistently infected patient. (E) Ratio of the magnitude of the T cell response to RTC/structural T cells. Percentage of cohort with a response above 1 (stronger response to RTC than structural proteins) shown below. (F) Magnitude of T cell response to a pool of epitopes from Flu, EBV, and CMV. (B–E) Subset of data previously published in Swadling et al. (A–F) IFNγ-ELISpot. (C and D) Box and Whisker, Tukey. (C–F) Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p < 0.0001. (E and F) Bars, geomean.
    Mabtech Elispot Reader, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/elispot+fluorospot+iris+mabtech+reader/bio_rxiv__64898__2026__03__12__711389-106-6-9
    Average 86 stars, based on 1 article reviews
    mabtech elispot reader - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Mabtech Inc elispot reader mabtech astortm2
    Magnitude and specificity of T cell memory responses generated by 899-day infection (A) Ex vivo <t>IFNγ-ELISpot</t> well images. DMSO control unstimulated wells and wells stimulated with overlapping peptides covering S1 and S2 region of Spike (duplicates shown), or single peptides S51 and S134. (B) Total magnitude of SARS-CoV-2-specific memory T cell response to structural proteins Spike, membrane (M), nucleoprotein (NP) and open reading frame 3a (ORF3a) and RTC proteins (NSP7, NSP12 polymerase, and NSP13 helicase) colored by protein targeted and measured after persistent infection (>900 days). (C and D) Total magnitude of SARS-CoV-2-specific T cell response (C) or T cell response to Structural and RTC proteins (D) in pre-pandemic samples (pre-August 2019), in exposed healthcare workers (HCW) who remained seronegative, including abortive infections, and in HCW with laboratory confirmed SARS-CoV-2 infections (samples 4 months post-exposure/infection in June to July 2020) for comparison to T cell response in persistently infected patient. (E) Ratio of the magnitude of the T cell response to RTC/structural T cells. Percentage of cohort with a response above 1 (stronger response to RTC than structural proteins) shown below. (F) Magnitude of T cell response to a pool of epitopes from Flu, EBV, and CMV. (B–E) Subset of data previously published in Swadling et al. (A–F) IFNγ-ELISpot. (C and D) Box and Whisker, Tukey. (C–F) Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p < 0.0001. (E and F) Bars, geomean.
    Elispot Reader Mabtech Astortm2, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/elispot+fluorospot+iris+mabtech+reader/pm41796205-146-6-8
    Average 86 stars, based on 1 article reviews
    elispot reader mabtech astortm2 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Mabtech Inc iristm elispot fluorospot reader
    Magnitude and specificity of T cell memory responses generated by 899-day infection (A) Ex vivo <t>IFNγ-ELISpot</t> well images. DMSO control unstimulated wells and wells stimulated with overlapping peptides covering S1 and S2 region of Spike (duplicates shown), or single peptides S51 and S134. (B) Total magnitude of SARS-CoV-2-specific memory T cell response to structural proteins Spike, membrane (M), nucleoprotein (NP) and open reading frame 3a (ORF3a) and RTC proteins (NSP7, NSP12 polymerase, and NSP13 helicase) colored by protein targeted and measured after persistent infection (>900 days). (C and D) Total magnitude of SARS-CoV-2-specific T cell response (C) or T cell response to Structural and RTC proteins (D) in pre-pandemic samples (pre-August 2019), in exposed healthcare workers (HCW) who remained seronegative, including abortive infections, and in HCW with laboratory confirmed SARS-CoV-2 infections (samples 4 months post-exposure/infection in June to July 2020) for comparison to T cell response in persistently infected patient. (E) Ratio of the magnitude of the T cell response to RTC/structural T cells. Percentage of cohort with a response above 1 (stronger response to RTC than structural proteins) shown below. (F) Magnitude of T cell response to a pool of epitopes from Flu, EBV, and CMV. (B–E) Subset of data previously published in Swadling et al. (A–F) IFNγ-ELISpot. (C and D) Box and Whisker, Tukey. (C–F) Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p < 0.0001. (E and F) Bars, geomean.
    Iristm Elispot Fluorospot Reader, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elispot+reader/elispot+fluorospot+iris+mabtech+reader/pm41763455-76-11-16
    Average 86 stars, based on 1 article reviews
    iristm elispot fluorospot reader - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    Magnitude and specificity of T cell memory responses generated by 899-day infection (A) Ex vivo IFNγ-ELISpot well images. DMSO control unstimulated wells and wells stimulated with overlapping peptides covering S1 and S2 region of Spike (duplicates shown), or single peptides S51 and S134. (B) Total magnitude of SARS-CoV-2-specific memory T cell response to structural proteins Spike, membrane (M), nucleoprotein (NP) and open reading frame 3a (ORF3a) and RTC proteins (NSP7, NSP12 polymerase, and NSP13 helicase) colored by protein targeted and measured after persistent infection (>900 days). (C and D) Total magnitude of SARS-CoV-2-specific T cell response (C) or T cell response to Structural and RTC proteins (D) in pre-pandemic samples (pre-August 2019), in exposed healthcare workers (HCW) who remained seronegative, including abortive infections, and in HCW with laboratory confirmed SARS-CoV-2 infections (samples 4 months post-exposure/infection in June to July 2020) for comparison to T cell response in persistently infected patient. (E) Ratio of the magnitude of the T cell response to RTC/structural T cells. Percentage of cohort with a response above 1 (stronger response to RTC than structural proteins) shown below. (F) Magnitude of T cell response to a pool of epitopes from Flu, EBV, and CMV. (B–E) Subset of data previously published in Swadling et al. (A–F) IFNγ-ELISpot. (C and D) Box and Whisker, Tukey. (C–F) Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p < 0.0001. (E and F) Bars, geomean.

    Journal: iScience

    Article Title: Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host

    doi: 10.1016/j.isci.2026.114917

    Figure Lengend Snippet: Magnitude and specificity of T cell memory responses generated by 899-day infection (A) Ex vivo IFNγ-ELISpot well images. DMSO control unstimulated wells and wells stimulated with overlapping peptides covering S1 and S2 region of Spike (duplicates shown), or single peptides S51 and S134. (B) Total magnitude of SARS-CoV-2-specific memory T cell response to structural proteins Spike, membrane (M), nucleoprotein (NP) and open reading frame 3a (ORF3a) and RTC proteins (NSP7, NSP12 polymerase, and NSP13 helicase) colored by protein targeted and measured after persistent infection (>900 days). (C and D) Total magnitude of SARS-CoV-2-specific T cell response (C) or T cell response to Structural and RTC proteins (D) in pre-pandemic samples (pre-August 2019), in exposed healthcare workers (HCW) who remained seronegative, including abortive infections, and in HCW with laboratory confirmed SARS-CoV-2 infections (samples 4 months post-exposure/infection in June to July 2020) for comparison to T cell response in persistently infected patient. (E) Ratio of the magnitude of the T cell response to RTC/structural T cells. Percentage of cohort with a response above 1 (stronger response to RTC than structural proteins) shown below. (F) Magnitude of T cell response to a pool of epitopes from Flu, EBV, and CMV. (B–E) Subset of data previously published in Swadling et al. (A–F) IFNγ-ELISpot. (C and D) Box and Whisker, Tukey. (C–F) Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p < 0.0001. (E and F) Bars, geomean.

    Article Snippet: Plates were washed in double-distilled H 2 O and left to dry overnight before being read on the AID classic ELISpot plate reader (Immunospot S6 Universal M2 ELISpot Reader).

    Techniques: Generated, Infection, Ex Vivo, Enzyme-linked Immunospot, Control, Membrane, Comparison, Whisker Assay

    Failure of host T cells to recognize emerging virus (A) Ex vivo magnitude of the T cell response to individual ancestral sequence peptides in which mutation arose over persistent infection by IFNγ-ELISpot. (B) Magnitude of the CD4 and CD8 T cell responses after 10-day in vitro peptide expansion with individual ancestral sequence peptides. Percentage of CD4 and CD8 producing IFNγ, TNF, or both are shown. (C) Magnitude of IFNγ+, IFNγ+TNF+, and CTV lo IFNγ+ CD4 and CD8 T cells after 8-day expansion with a pool of 12 peptides corresponding to ancestral sequence epitopes or variant sequence epitopes containing mutations in the virus isolated at day 899 of infection. (D) Magnitude of the IFNγ+TNF+ CD4 or CD8 T cell response after 10-day in vitro peptide stimulation with individual epitopes using ancestral sequence or variant sequence peptides for culture and re-stimulation on day 9. Summary data showing all T cell responses that were detectable (left) or shown for individual peptides (right) for CD4 then CD8 T cells. Duplicate and triplicate stimulations are shown for CD8 T cells for M14 and NSP2, respectively. (D) Bars, mean. Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗∗ p ≤ 0.001. Peptide sequences shown in .

    Journal: iScience

    Article Title: Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host

    doi: 10.1016/j.isci.2026.114917

    Figure Lengend Snippet: Failure of host T cells to recognize emerging virus (A) Ex vivo magnitude of the T cell response to individual ancestral sequence peptides in which mutation arose over persistent infection by IFNγ-ELISpot. (B) Magnitude of the CD4 and CD8 T cell responses after 10-day in vitro peptide expansion with individual ancestral sequence peptides. Percentage of CD4 and CD8 producing IFNγ, TNF, or both are shown. (C) Magnitude of IFNγ+, IFNγ+TNF+, and CTV lo IFNγ+ CD4 and CD8 T cells after 8-day expansion with a pool of 12 peptides corresponding to ancestral sequence epitopes or variant sequence epitopes containing mutations in the virus isolated at day 899 of infection. (D) Magnitude of the IFNγ+TNF+ CD4 or CD8 T cell response after 10-day in vitro peptide stimulation with individual epitopes using ancestral sequence or variant sequence peptides for culture and re-stimulation on day 9. Summary data showing all T cell responses that were detectable (left) or shown for individual peptides (right) for CD4 then CD8 T cells. Duplicate and triplicate stimulations are shown for CD8 T cells for M14 and NSP2, respectively. (D) Bars, mean. Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗∗ p ≤ 0.001. Peptide sequences shown in .

    Article Snippet: Plates were washed in double-distilled H 2 O and left to dry overnight before being read on the AID classic ELISpot plate reader (Immunospot S6 Universal M2 ELISpot Reader).

    Techniques: Virus, Ex Vivo, Sequencing, Mutagenesis, Infection, Enzyme-linked Immunospot, In Vitro, Variant Assay, Isolation